Table 1.
Quantitative immunohistochemistry (IHC) analysis of the biomarkers.
| Biomarkers | Experimental Groups | |||||
|---|---|---|---|---|---|---|
| ConG | JG | JDG | PG | PDG | WT | |
| GFAP H | ++ | ++ | ++ | ++++ | +++ | ++++ |
| GFAP SC | ++ | ++ | ++ | +++ | ++ | +++ |
| S100 H | ++ | ++ | ++ | ++++ | +++ | +++ |
| S100 SC | ++ | ++ | ++ | +++ | ++ | ++++ |
| M1 AChR H | + | +++ | +++ | +++ | ++ | ++++ |
| M1 AchR SC | + | +++ | ++ | ++ | +++ | ++++ |
| mTOR H | +++ | ++ | ++ | ++ | ++ | +++ |
| mTOR SC | ++++ | + | + | ++ | ++ | ++ |
| CB2 H | ++++ | ++ | ++ | +++ | +++ | + |
| CB2 SC | +++ | ++ | ++ | +++ | ++ | + |
Average IHC positive cells/10 fields of 10,000 μm2; 1–6 IHC + positive cells; 6–12 IHC ++ positive cells; 12–18 IHC +++ positive cells; 18–24 IHC positive cells ++++; SC: subcortical area; H: hippocampus area; ConG: control group; JG: JWH-133 group; JDG: JWH-133 + donepezil group; PG: Cannabixir® Medium Flos group; PDG: Cannabixir® Medium Flos + donepezil group; WT: vehicle group; mTOR: mammalian target of rapamycin; M1mAChR: muscarinic acetylcholine receptor M1; CB2: cannabinoid receptor type 2.